Related Articles for PubMed (Select 15784149)

The antitumor immune response in HER-2 positive, metastatic breast cancer patients.

Juranic ZD, Neskovic-Konstantinovic Z, Stanojkovic TP, Zizak Z, Srdic T, Stanojevic-Bakic N, Milosevic D, Jovanovic D.

J Transl Med. 2005 Mar 22;3(1):13.

PMID: 15784149 [PubMed - as supplied by publisher]

Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.

Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.

Cancer Res. 2006 Jul 15;66(14):7245-52.

PMID: 16849573 [PubMed - indexed for MEDLINE]

Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.

Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M.

Anticancer Res. 2003 Nov-Dec;23(6a):4443-9.

PMID: 14666732 [PubMed - indexed for MEDLINE]

Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells.

Bocangel D, Zheng M, Mhashilkar A, Liu Y, Ramesh R, Hunt KK, Chada S.

Cancer Gene Ther. 2006 Oct;13(10):958-68. Epub 2006 Jun 16.

PMID: 16783343 [PubMed - indexed for MEDLINE]

Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.

Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, Matsumoto Y.

Cancer Res. 2002 Oct 15;62(20):5813-7.

PMID: 12384543 [PubMed - indexed for MEDLINE]

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID: 17993229 [PubMed - indexed for MEDLINE]

Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.

Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.

Int J Oncol. 2004 Mar;24(3):591-608.

PMID: 14767544 [PubMed - indexed for MEDLINE]

Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck.

Bier H, Hoffmann T, Haas I, van Lierop A.

Cancer Immunol Immunother. 1998 May;46(3):167-73.

PMID: 9625540 [PubMed - indexed for MEDLINE]

Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.

Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W.

Cancer Res. 1998 Feb 15;58(4):732-6.

PMID: 9485028 [PubMed - indexed for MEDLINE]

10:

Overexpression of HER-2/neu in uterine serous papillary cancer.

Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP.

Clin Cancer Res. 2002 May;8(5):1271-9.

PMID: 12006548 [PubMed - indexed for MEDLINE]

11:

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.

Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.

Oncogene. 1998 Oct 29;17(17):2235-49.

PMID: 9811454 [PubMed - indexed for MEDLINE]

12:

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.

Parihar R, Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, VanBuskirk AM, Magro CM, Young DC, Shapiro CL, Carson WE 3rd.

Clin Cancer Res. 2004 Aug 1;10(15):5027-37.

PMID: 15297404 [PubMed - indexed for MEDLINE]

13:

Effects of X-ray irradiation on the overexpression of HER-2/Erb-B2 on breast cancer cell lines.

Juranić ZD, Borojević N, Jovanović D, Stanojević-Bakić N, Zizak Z, Nesković-Konstantinović Z, Sarić M, Stanojković T, Raonić T, Milosević D.

J Exp Clin Cancer Res. 2004 Dec;23(4):675-80.

PMID: 15743039 [PubMed - indexed for MEDLINE]

14:

Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.

Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD.

Gynecol Oncol. 2003 Oct;91(1):231-40.

PMID: 14529687 [PubMed - indexed for MEDLINE]

15:

Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.

Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M.

Cancer. 1994 Aug 15;74(4):1275-82.

PMID: 7914469 [PubMed - indexed for MEDLINE]

16:

Induction of cytotoxicity against autologous tumour cells by interleukin-12: evidence for intrinsic anti-tumor immune capacity in curatively resected gastrointestinal tumour patients.

Ströhlein MA, Grützner KU, Schildberg FW, Heiss MM.

Cancer Immunol Immunother. 2002 Nov;51(9):505-12. Epub 2002 Sep 4.

PMID: 12357322 [PubMed - indexed for MEDLINE]

17:

Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.

Chen P, Cameron R, Wang J, Vallis KA, Reilly RM.

J Nucl Med. 2003 Sep;44(9):1469-78.

PMID: 12960194 [PubMed - indexed for MEDLINE]

18:

Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status.

Grupka NL, Lear-Kaul KC, Kleinschmidt-DeMasters BK, Singh M.

Arch Pathol Lab Med. 2004 Sep;128(9):974-9.

PMID: 15335267 [PubMed - indexed for MEDLINE]

19:

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.

Cardoso F, Durbecq V, Laes JF, Badran B, Lagneaux L, Bex F, Desmedt C, Willard-Gallo K, Ross JS, Burny A, Piccart M, Sotiriou C.

Mol Cancer Ther. 2006 Dec;5(12):3042-51. Epub 2006 Dec 5.

PMID: 17148762 [PubMed - indexed for MEDLINE]

20:

Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.

Warburton C, Dragowska WH, Gelmon K, Chia S, Yan H, Masin D, Denyssevych T, Wallis AE, Bally MB.

Clin Cancer Res. 2004 Apr 1;10(7):2512-24.

PMID: 15073131 [PubMed - indexed for MEDLINE]

Recent Activity